Advertisement

Drugs

, Volume 78, Issue 3, pp 397–397 | Cite as

Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma

  • Hannah A. Blair
Correction
  • 1k Downloads

1 Correction to: Drugs (2017) 77:2013–2024  https://doi.org/10.1007/s40265-017-0837-7

The author has alerted us to the following error in Sect. 4.2.2.1, and the following correction should be noted:

Page 2019, Sect. 4.2.2.1, paragraph 1, lines 6–10: the following sentence, which previously read:

“After a median follow-up of 24.5 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p < 0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31–0.53)”.

should read:

“After a median follow-up of 25.4 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p < 0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31–0.53)”.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations